olorofim
Selected indexed studies
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. (Drugs, 2021) [PMID:34626339]
- Review of the novel antifungal drug olorofim (F901318). (BMC Infect Dis, 2024) [PMID:39511507]
- Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. (Lancet Infect Dis, 2025) [PMID:40541222]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. (2021) pubmed
- Review of the novel antifungal drug olorofim (F901318). (2024) pubmed
- Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. (2025) pubmed
- The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies. (2024) pubmed
- EUCAST olorofim MICs for 3,550 Danish mold and dermatophyte isolates from 2020 to 2023. (2025) pubmed
- Review of the Novel Investigational Antifungal Olorofim. (2020) pubmed
- Olorofim Effectively Eradicates Dermatophytes In Vitro and In Vivo. (2021) pubmed
- Olorofim activity against multidrug-resistant Fusarium unveils intra-species and inter-species variability. (2025) pubmed
- Olorofim: addressing unmet needs of patients with difficult-to-treat fungal infections. (2025) pubmed
- Anti-Aspergillus activities of olorofim at sub-MIC levels during early-stage growth. (2024) pubmed